Lusutrombopag Increases Hematocytes in a Compensated Liver Cirrhosis Patient

Overview

Journal Clin J Gastroenterol

Specialty Gastroenterology

Date 2017 Mar 22

PMID 28324272

Citations 8

Authors

Akira Sakamaki

Takayuki Watanabe

Satoshi Abe

Kenya Kamimura

Atsunori Tsuchiya

Masaaki Takamura

Hirokazu Kawai

Satoshi Yamagiwa

Shuji Terai

Affiliations

Soon will be listed here.

Abstract

A 56-year-old Japanese man with liver cirrhosis (LC) due to hepatitis C virus was admitted to our hospital for radiofrequency ablation of residual tumor following lusutrombopag administration. Laboratory tests revealed thrombocytopenia and leukopenia. The patient's LC was managed, and he was classified as Child-Pugh A. After admission, lusutrombopag was administered for 7 days. The platelet count increased to over 50,000/mm after 7-14 days and returned to previous levels 50 days after administration. Leukocyte and erythrocyte counts also increased in response to the treatment and stayed elevated for over 120 days. Lusutrombopag acts selectively on human thrombopoietin (TPO) receptors and activates signaling pathways that promote the proliferation and differentiation of bone marrow progenitor cells into megakaryocytes, consequently increasing the blood platelet count. However, the patient treated with lusutrombopag in our case study showed increased blood leukocyte and erythrocyte counts as well. Given that TPO receptors are reportedly expressed in not only megakaryocyte progenitor cells but also hematopoietic progenitors, lusutrombopag may potentially improve pancytopenia caused by LC and can be used for the recovery of blood counts before other treatments.

Citing Articles

Dualistic role of platelets in living donor liver transplantation: Are they harmful?.

Liang C, Takahashi K, Furuya K, Ohkohchi N, Oda T World J Gastroenterol. 2022; 28(9):897-908.

PMID: 35317052 PMC: 8908284. DOI: 10.3748/wjg.v28.i9.897.

Pharmacokinetics of Lusutrombopag, a Novel Thrombopoietin Receptor Agonist, in Rats by UPLC-MS/MS.

Wang B, Chen F, Zhou Q, Zhou Y, Meng D, Geng P Int J Anal Chem. 2020; 2020:7290470.

PMID: 32550846 PMC: 7277053. DOI: 10.1155/2020/7290470.

Thrombocytopenia and Procedural Prophylaxis in the Era of Thrombopoietin Receptor Agonists.

Nilles K, Caldwell S, Flamm S Hepatol Commun. 2019; 3(11):1423-1434.

PMID: 31701067 PMC: 6824078. DOI: 10.1002/hep4.1423.

Current Advance in Thrombopoietin Receptor Agonists in the Management of Thrombocytopenia Associated With Chronic Liver Disease: Focus on Avatrombopag.

Abdela J Clin Med Insights Blood Disord. 2019; 12:1179545X19875105.

PMID: 31673229 PMC: 6804364. DOI: 10.1177/1179545X19875105.

Immunological consequences following splenectomy in patients with liver cirrhosis.

Hirakawa Y, Ogata T, Sasada T, Yamashita T, Itoh K, Tanaka H Exp Ther Med. 2019; 18(1):848-856.

PMID: 31281459 PMC: 6591499. DOI: 10.3892/etm.2019.7640.

References

Ooi J, Tojo A, Asano S, Sato Y, Oka Y . Thrombopoietin induces tyrosine phosphorylation of a common beta subunit of GM-CSF receptor and its association with Stat5 in TF-1/TPO cells. Biochem Biophys Res Commun. 1998; 246(1):132-6. DOI: 10.1006/bbrc.1998.8588. View

Livraghi T, Solbiati L, Meloni M, Gazelle G, Halpern E, Goldberg S . Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. Radiology. 2003; 226(2):441-51. DOI: 10.1148/radiol.2262012198. View

Tateishi R, Shiina S, Teratani T, Obi S, Sato S, Koike Y . Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. Cancer. 2005; 103(6):1201-9. DOI: 10.1002/cncr.20892. View

Kuter D, Beeler D, Rosenberg R . The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci U S A. 1994; 91(23):11104-8. PMC: 45175. DOI: 10.1073/pnas.91.23.11104. View

Gao B, Li Z, Xue D, Zhang W . A novel mechanism of abnormal hematological indices in liver cirrhosis: bone marrow endothelial cell dysfunction caused by humoral inhibitor affects the hematopoietic function of bone marrow. Med Hypotheses. 2014; 82(3):282-5. DOI: 10.1016/j.mehy.2013.12.010. View

Zeigler F, De Sauvage F, Widmer H, Keller G, Donahue C, Schreiber R . In vitro megakaryocytopoietic and thrombopoietic activity of c-mpl ligand (TPO) on purified murine hematopoietic stem cells. Blood. 1994; 84(12):4045-52. View

Kim E . Lusutrombopag: First Global Approval. Drugs. 2015; 76(1):155-8. DOI: 10.1007/s40265-015-0525-4. View

Okubo M, Shiota G, Kawasaki H . Thrombopoietin levels in serum and liver tissue in patients with chronic viral hepatitis and hepatocellular carcinoma. Clin Sci (Lond). 2002; 99(3):207-14. View

Nurden A, Viallard J, Nurden P . New-generation drugs that stimulate platelet production in chronic immune thrombocytopenic purpura. Lancet. 2009; 373(9674):1562-9. DOI: 10.1016/S0140-6736(09)60255-5. View

10.

Rios R, Sangro B, Herrero I, Quiroga J, Prieto J . The role of thrombopoietin in the thrombocytopenia of patients with liver cirrhosis. Am J Gastroenterol. 2005; 100(6):1311-6. DOI: 10.1111/j.1572-0241.2005.41543.x. View

11.

Witters P, Freson K, Verslype C, Peerlinck K, Hoylaerts M, Nevens F . Review article: blood platelet number and function in chronic liver disease and cirrhosis. Aliment Pharmacol Ther. 2008; 27(11):1017-29. DOI: 10.1111/j.1365-2036.2008.03674.x. View

12.

Olnes M, Scheinberg P, Calvo K, Desmond R, Tang Y, Dumitriu B . Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med. 2012; 367(1):11-9. PMC: 3422737. DOI: 10.1056/NEJMoa1200931. View

13.

Afdhal N, Giannini E, Tayyab G, Mohsin A, Lee J, Andriulli A . Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. N Engl J Med. 2012; 367(8):716-24. DOI: 10.1056/NEJMoa1110709. View

14.

Guo T, Wang X, Qu Y, Yin Y, Jing T, Zhang Q . Megakaryopoiesis and platelet production: insight into hematopoietic stem cell proliferation and differentiation. Stem Cell Investig. 2016; 2:3. PMC: 4923649. DOI: 10.3978/j.issn.2306-9759.2015.02.01. View

15.

Kovtonyuk L, Manz M, Takizawa H . Enhanced thrombopoietin but not G-CSF receptor stimulation induces self-renewing hematopoietic stem cell divisions in vivo. Blood. 2016; 127(25):3175-9. DOI: 10.1182/blood-2015-09-669929. View